Chemoprevention of colorectal cancer in individuals with previous colorectal neoplasia: Systematic review and network meta-analysis

BMJ (Online)

Volumn 355, Issue , 2016, Pages

  Dulai, Parambir S ^a   Singh, Siddharth ^a   Marquez, Evelyn ^a   Khera, Rohan ^b   Prokop, Larry J ^c   Limburg, Paul J ^c   Gupta, Samir ^c,d,e   Murad, Mohammad Hassan ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

^c MAYO CLINIC   (United States)

^d VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^e UNIVERSITY OF SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CALCIUM; FOLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; VITAMIN D; VITAMIN; VITAMIN B COMPLEX;

ADULT; ADVANCED CANCER; BAYES THEOREM; CANCER MORTALITY; CHEMOPROPHYLAXIS; COLONOSCOPY; COLORECTAL CANCER; COLORECTAL TUMOR; COMPARATIVE STUDY; DECISION MAKING; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; HEALTH CARE COST; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; COLORECTAL NEOPLASMS; NETWORK META-ANALYSIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; BAYES THEOREM; CALCIUM; CHEMOPREVENTION; COLORECTAL NEOPLASMS; FOLIC ACID; HUMANS; NETWORK META-ANALYSIS; VITAMIN B COMPLEX; VITAMIN D; VITAMINS;

EID: 85002766016     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.i6188     Document Type: Review

References (64)

1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-86. doi:10. 1002/ijc. 29210.
2. Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst 2011;103:117-28. doi:10. 1093/jnci/djq495.
3. Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet 2014;383:1490-502. doi:10. 1016/S0140-6736(13)61649-9.
4. Nishihara R, Wu K, Lochhead P, et al. Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med 2013;369:1095-105. doi:10. 1056/NEJMoa1301969.
5. Brenner H, Stock C, Hoffmeister M. Effect of screening sigmoidoscopy and screening colonoscopy on colorectal cancer incidence and mortality: systematic review and meta-analysis of randomised controlled trials and observational studies. BMJ 2014;348:g2467. doi:10. 1136/bmj. g2467.
6. Schreuders EH, Ruco A, Rabeneck L, et al. Colorectal cancer screening: a global overview of existing programmes. Gut 2015;64:1637-49. doi:10. 1136/gutjnl-2014-309086.
7. Singh S, Singh PP, Murad MH, Singh H, Samadder NJ. Prevalence, risk factors, outcomes of interval colorectal cancers: a systematic review and meta-analysis. Am J Gastroenterol 2014;109:1375-89. doi:10. 1038/ajg. 2014. 171.
8. Adler J, Robertson DJ. Interval Colorectal Cancer After Colonoscopy: Exploring Explanations and Solutions. Am J Gastroenterol 2015;110:1657-64, quiz 1665. doi:10. 1038/ajg. 2015. 365.
9. Arber N, Eagle CJ, Spicak J, et al. PreSAP Trial Investigators. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006;355:885-95. doi:10. 1056/NEJMoa061652.
10. Baron JA, Barry EL, Mott LA, et al. A Trial of Calcium and Vitamin D for the Prevention of Colorectal Adenomas. N Engl J Med 2015;373:1519-30. doi:10. 1056/NEJMoa1500409.
11. Baron JA, Beach M, Mandel JS, et al. Calcium Polyp Prevention Study Group. Calcium supplements for the prevention of colorectal adenomas. N Engl J Med 1999;340:101-7. doi:10. 1056/NEJM199901143400204.
12. Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003;348:891-9. doi:10. 1056/NEJMoa021735.
13. Benamouzig R, Deyra J, Martin A, et al. Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology 2003;125:328-36. doi:10. 1016/S0016-5085(03)00887-4.
14. Bertagnolli MM, Eagle CJ, Zauber AG, et al. APC Study Investigators. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006;355:873-84. doi:10. 1056/NEJMoa061355.
15. Bonithon-Kopp C, Kronborg O, Giacosa A, Räth U, Faivre J. European Cancer Prevention Organisation Study Group. Calcium and fibre supplementation in prevention of colorectal adenoma recurrence: a randomised intervention trial. Lancet 2000;356:1300-6. doi:10. 1016/S0140-6736(00)02813-0.
16. Chu DZ, Hussey MA, Alberts DS, et al. Colorectal Chemoprevention Pilot Study (SWOG-9041), randomized and placebo controlled: the importance of multiple luminal lesions. Clin Colorectal Cancer 2011;10:310-6. doi:10. 1016/j. clcc. 2011. 06. 005.
17. Cole BF, Baron JA, Sandler RS, et al. Polyp Prevention Study Group. Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. JAMA 2007;297:2351-9. doi:10. 1001/jama. 297. 21. 2351.
18. Ishikawa H, Mutoh M, Suzuki S, et al. The preventive effects of low-dose enteric-coated aspirin tablets on the development of colorectal tumours in Asian patients: a randomised trial. Gut 2014;63:1755-9. doi:10. 1136/gutjnl-2013-305827.
19. Logan RF, Grainge MJ, Shepherd VC, Armitage NC, Muir KR. ukCAP Trial Group. Aspirin and folic acid for the prevention of recurrent colorectal adenomas. Gastroenterology 2008;134:29-38. doi:10. 1053/j. gastro. 2007. 10. 014.
20. Meyskens FL Jr, McLaren CE, Pelot D, et al. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res (Phila) 2008;1:32-8. doi:10. 1158/1940-6207. CAPR-08-0042.
21. Pommergaard HC, Burcharth J, Rosenberg J, Raskov H. Aspirin, Calcitriol, Calcium Do Not Prevent Adenoma Recurrence in a Randomized Controlled Trial. Gastroenterology 2016;150:114-122. e4. doi:10. 1053/j. gastro. 2015. 09. 010.
22. Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003;348:883-90. doi:10. 1056/NEJMoa021633.
23. Wu K, Platz EA, Willett WC, et al. A randomized trial on folic acid supplementation and risk of recurrent colorectal adenoma. Am J Clin Nutr 2009;90:1623-31. doi:10. 3945/ajcn. 2009. 28319.
24. Cole BF, Logan RF, Halabi S, et al. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst 2009;101:256-66. doi:10. 1093/jnci/djn485.
25. Cooper K, Squires H, Carroll C, et al. Chemoprevention of colorectal cancer: systematic review and economic evaluation. Health Technol Assess 2010;14:1-206. doi:10. 3310/hta14320.
26. Rostom A, Dubé C, Lewin G, et al. U. S. Preventive Services Task Force. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U. S. Preventive Services Task Force. Ann Intern Med 2007;146:376-89. doi:10. 7326/0003-4819-146-5-200703060-00010.
27. Cipriani A, Higgins JP, Geddes JR, Salanti G. Conceptual and technical challenges in network meta-analysis. Ann Intern Med 2013;159:130-7. doi:10. 7326/0003-4819-159-2-201307160-00008.
28. Mills EJ, Ioannidis JP, Thorlund K, Schünemann HJ, Puhan MA, Guyatt GH. How to use an article reporting a multiple treatment comparison meta-analysis. JAMA 2012;308:1246-53. doi:10. 1001/2012. jama. 11228.
29. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004;23:3105-24. doi:10. 1002/sim. 1875.
30. Puhan MA, Schünemann HJ, Murad MH, et al. GRADE Working Group. A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ 2014;349:g5630. doi:10. 1136/bmj. g5630.
31. Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 2015;162:777-84. doi: 10. 7326/M14-2385.
32. Hoaglin DC, Hawkins N, Jansen JP, et al. Conducting indirecttreatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. Value Health 2011;14:429-37. doi:10. 1016/j. jval. 2011. 01. 011.
33. Wolff WI. Colonoscopy: history and development. Am J Gastroenterol 1989;84:1017-25.
34. Bertagnolli MM, Eagle CJ, Zauber AG, et al. Adenoma Prevention with Celecoxib Study Investigators. Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. Cancer Prev Res (Phila) 2009;2:310-21. doi:10. 1158/1940-6207. CAPR-08-0206.
35. Arber N, Spicak J, Rácz I, et al. Five-year analysis of the prevention of colorectal sporadic adenomatous polyps trial. Am J Gastroenterol 2011;106:1135-46. doi:10. 1038/ajg. 2011. 116.
36. Chu DZ, Chansky K, Alberts DS, et al. Adenoma recurrences after resection of colorectal carcinoma: results from the Southwest Oncology Group 9041 calcium chemoprevention pilot study. Ann Surg Oncol 2003;10:870-5. doi:10. 1245/ASO. 2003. 03. 037.
37. Lieberman DA, Rex DK, Winawer SJ, Giardiello FM, Johnson DA, Levin TR. United States Multi-Society Task Force on Colorectal Cancer. Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology 2012;143:844-57. doi:10. 1053/j. gastro. 2012. 06. 001.
38. Higgins JPT Green S, ed. Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Collaboration, 2011. http://www. handbook. cochrane. org.
39. Brenner H, Altenhofen L, Stock C, Hoffmeister M. Natural history of colorectal adenomas: birth cohort analysis among 3. 6 million participants of screening colonoscopy. Cancer Epidemiol Biomarkers Prev 2013;22:1043-51. doi:10. 1158/1055-9965. EPI-13-0162.
40. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88. doi:10. 1016/0197-2456(86)90046-2.
41. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60. doi:10. 1136/bmj. 327. 7414. 557.
42. Hartung J, Knapp G. A refined method for the meta-analysis of controlled clinical trials with binary outcome. Stat Med 2001;20:3875-89. doi:10. 1002/sim. 1009.
43. Dias S, Sutton AJ, Ades AE, Welton NJ. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med Decis Making 2013;33:607-17. doi:10. 1177/0272989X12458724.
44. Khera R, Murad MH, Chandar AK, et al. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis. JAMA 2016;315:2424-34. doi:10. 1001/jama. 2016. 7602.
45. Gelman ARD. Inference from iterative simulation using multiple sequences. Stat Sci 1992;7:457-511doi:10. 1214/ss/1177011136.
46. Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol 2011;64:163-71. doi:10. 1016/j. jclinepi. 2010. 03. 016.
47. Chaimani A, Higgins JP, Mavridis D, Spyridonos P, Salanti G. Graphical tools for network meta-analysis in STATA. PLoS One 2013;8:e76654. doi:10. 1371/journal. pone. 0076654.
48. Zhang J, Yu KF. What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA 1998;280:1690-1. doi:10. 1001/jama. 280. 19. 1690.
49. Singh S, Khera R, Allen AM, Murad MH, Loomba R. Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta-analysis. Hepatology 2015;62:1417-32. doi:10. 1002/hep. 27999.
50. Martínez ME, Baron JA, Lieberman DA, et al. A pooled analysis of advanced colorectal neoplasia diagnoses after colonoscopic polypectomy. Gastroenterology 2009;136:832-41. doi:10. 1053/j. gastro. 2008. 12. 007.
51. Chan AT, Ladabaum U. Where Do We Stand With Aspirin for the Prevention of Colorectal Cancer? The USPSTF Recommendations. Gastroenterology 2016;150:14-8. doi:10. 1053/j. gastro. 2015. 11. 018.
52. Chubak J, Kamineni A, Buist DSM, et al. U. S. Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews. Aspirin Use for the Prevention of Colorectal Cancer: An Updated Systematic Evidence Review for the US Preventive Services Task Force. Rockville (MD). Agency for Healthcare Research and Quality, 2015.
53. Johnson MR, Grubber J, Grambow SC, et al. Physician Non-adherence to Colonoscopy Interval Guidelines in the Veterans Affairs Healthcare System. Gastroenterology 2015;149:938-51. doi:10. 1053/j. gastro. 2015. 06. 026.
54. Murphy CC, Lewis CL, Golin CE, Sandler RS. Underuse of surveillance colonoscopy in patients at increased risk of colorectal cancer. Am J Gastroenterol 2015;110:633-41. doi:10. 1038/ajg. 2014. 344.
55. Mysliwiec PA, Brown ML, Klabunde CN, Ransohoff DF. Are physicians doing too much colonoscopy? A national survey of colorectal surveillance after polypectomy. Ann Intern Med 2004;141:264-71. doi:10. 7326/0003-4819-141-4-200408170-00006.
56. Patel N, Tong L, Ahn C, Singal AG, Gupta S. Post-polypectomy Guideline Adherence: Importance of Belief in Guidelines, Not Guideline Knowledge or Fear of Missed Cancer. Dig Dis Sci 2015;60:2937-45. doi:10. 1007/s10620-015-3685-x.
57. Mainous AG, Tanner RJ, Shorr RI, Limacher MC. Use of aspirin for primary and secondary cardiovascular disease prevention in the United States, 2011-2012. J Am Heart Assoc 2014;3:e000989. doi:10. 1161/JAHA. 114. 000989.
58. Stafford RS, Monti V, Ma J. Underutilization of aspirin persists in US ambulatory care for the secondary and primary prevention of cardiovascular disease. PLoS Med 2005;2:e353. doi:10. 1371/journal. pmed. 0020353.
59. Rostom A, Dube C, Lewin GUS. Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews. Use of Aspirin and NSAIDs to Prevent Colorectal Cancer. Rockville (MD). Agency for Healthcare Research and Quality, 2007.
60. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006;296:1633-44. doi:10. 1001/jama. 296. 13. jrv60011.
61. Bello AE, Holt RJ. Cardiovascular risk with non-steroidal antiinflammatory drugs: clinical implications. Drug Saf 2014;37:897-902. doi:10. 1007/s40264-014-0207-2.
62. Drew DA, Cao Y, Chan AT. Aspirin and colorectal cancer: the promise of precision chemoprevention. Nat Rev Cancer 2016;16:173-86. doi:10. 1038/nrc. 2016. 4.
63. Nan H, Hutter CM, Lin Y, et al. CCFR GECCO. Association of aspirin and NSAID use with risk of colorectal cancer according to genetic variants. JAMA 2015;313:1133-42. doi:10. 1001/jama. 2015. 1815.
64. Roy HK, Turzhitsky V, Wali R, et al. Spectral biomarkers for chemoprevention of colonic neoplasia: a placebo-controlled double-blinded trial with aspirin. Gut 2015;gutjnl-2015-309996. doi:10. 1136/gutjnl-2015-309996.